Overview

Rectal Indomethacin in the Prevention of Post-endoscopic Retrograde Cholangiopancreatography (ERCP) Pancreatitis in High Risk Patients

Status:
Terminated

Trial end date:
2011-07-01

Target enrollment:

Participant gender:

Summary

Pancreatitis (inflammation of the pancreas) is the most common complication of endoscopic retrograde cholangiopancreatography (ERCP), a procedure for the diagnosis and treatment of disorders of the pancreas and bile duct. Preliminary data has shown that non-steroidal antiinflammatory drugs, when administered rectally, can reduce the risk of pancreatitis after ERCP. This study is intended to definitively determine whether rectally administered indomethacin (a non-steroidal antiinflammatory drug)is effective at preventing pancreatitis after ERCP.

Phase:

Phase 4

Details

Lead Sponsor:

University of Michigan

Collaborators:

Case Western Reserve University
Indiana University School of Medicine
University of Kentucky

Treatments:

Indomethacin